Published in

American Society for Microbiology, Journal of Virology, 3(96), 2022

DOI: 10.1128/jvi.01614-21

Links

Tools

Export citation

Search in Google Scholar

The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2 <sub>1-180</sub> ) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge

Journal article published in 2022 by Sergio Utrilla-Trigo, Luis Jiménez-Cabello, Eva Calvo-Pinilla ORCID, Alejandro Marín-López, Gema Lorenzo, Pedro Sánchez-Cordón, Sandra Moreno, Julio Benavides, Sarah Gilbert, Aitor Nogales ORCID, Javier Ortego ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Current BTV vaccines are effective but they do not allow to distinguish between vaccinated and infected animals (DIVA strategy) and are serotype specific. In this work we have develop a DIVA multiserotype vaccination strategy based on adenoviral (ChAdOx1) and MVA vaccine vectors, the most widely used in current phase I and II clinical trials, and the conserved nonstructural BTV proteins NS1 and NS2. This immunization strategy solves the major drawbacks of the current marketed vaccines.